Illumina fails to block EU antitrust review of $8B Grail merger

By siding with the European Commission, the General Court has cleared the EU to resume a review that could lead to it blocking the deal and fining Illumina.

By Nick Paul Taylor • July 18, 2022

Medtronic lands option to buy artery disease player CathWorks for up to $585M

CathWorks has the right to compel Medtronic to complete the acquisition if it chooses not to exercise its option.

By Nick Paul Taylor • July 13, 2022

Ex-Mazor executive charged by SEC with insider trading over Medtronic's $1.6B buyout

Doron Tavlin, who was Mazor’s vice president of business development, is accused by the agency of profiting from his inside knowledge of the pending takeover.

By Nick Paul Taylor • July 11, 2022

Medtech M&A falls 85% but activity could rebound in second half: report

PwC highlights a range of barriers that could stop acquisitions, including supply chain issues, scrutiny from the Federal Trade Commission and geopolitical concerns.

By Nick Paul Taylor • June 24, 2022

Bioventus agrees to staggered payment plan to close stalled $315M CartiHeal takeover

Rising interest rates quashed a plan for Bioventus to fund the takeover of the joint repair company with a bond offering. Now, the deal will get much more expensive, J.P. Morgan analysts said.

By Nick Paul Taylor • June 23, 2022

Boston Scientific inks $230M deal to buy majority stake in M.I.Tech

M.I.Tech is a South Korean manufacturer of endoscopic and urologic medical devices. Analysts at BTIG said the deal complements Boston Scientific’s non-vascular stent portfolio and boosts its international presence.

By Nick Paul Taylor • June 16, 2022

ResMed to acquire German health software company MediFox for $1B

The acquisition continues a pattern of medical device companies buying software platforms. ResMed expects the deal to close by the end of the year.

By Ricky Zipp • June 14, 2022

Oracle closes $28B buy of 'huge growth engine' Cerner

With the deal’s close, the days of standalone EHR vendors are increasingly in the rearview mirror.

By Rebecca Pifer • June 10, 2022

BD to acquire Parata for $1.53B as part of strategy to boost margins

The deal is expected to help Becton Dickinson reach its goal of a 25% operating margin by the end of 2025. J.P. Morgan analysts said it would be the most meaningful tuck-in deal since BD acquired Bard in 2017. 

By Elise Reuter • June 7, 2022

Boston Scientific would be 'good fit' for increasingly acquisitive J&J, analysts say

A limited portfolio overlap could make Boston Scientific a target should Johnson & Johnson's CEO seek a large medtech acquisition.

By Nick Paul Taylor • May 31, 2022

Baxter raises forecasts for Hillrom synergies, allaying concerns over $10.5B takeover

Company executives said the additional cost savings emerged as they took a closer look at Hillrom’s real estate footprint.

By Nick Paul Taylor • May 26, 2022

Medtronic completes Intersect acquisition following FTC order

The Federal Trade Commission required Medtronic to divest a subsidiary of Intersect ENT to complete the deal. Medtronic announced the $1.1 billion acquisition last August.

By Nick Paul Taylor • Updated May 16, 2022

Digital health funding dropped in Q1 to lowest level since 2020: CB Insights

The report is directionally in line with the findings of an earlier report from Rock Health, which described how the drying up of deals in February and March may be an early sign of a correction in digital health venture capital funding.

By Nick Paul Taylor • April 14, 2022

'Interesting anomaly': Hospital M&A fell to record low in Q1

Hospital M&A activity in the first quarter bucked last year's trends as both the amount and size of deals shrank, according to Kaufman Hall.

By Hailey Mensik • April 11, 2022

Illumina sues Guardant CEOs over trade secrets, sparking counterblast against 'retaliatory' lawsuit

Guardant called the lawsuit "frivolous and retaliatory" and framed it as a response to its concerns about the Illumina-Grail merger.

By Nick Paul Taylor • March 18, 2022

Akili plans to go public as it prepares to market video game treatment

"We've proven that foundation and now it's time to run and scale," CEO Eddie Martucci told MedTech Dive. The company is going public through a $1 billion SPAC, rather than a traditional IPO, which it expects to close in mid-2022.   

By Elise Reuter • March 10, 2022

DOJ moves forward with suit to block UnitedHealth's acquisition of Change

The lawsuit alleges that if UnitedHealth acquired Change, the payer would be able to gain a competitive advantage by seeing "very competitively sensitive" data from other insurers.

By Shannon Muchmore • Feb. 25, 2022

What does a more aggressive M&A approach mean for J&J's devices unit?

After medical device deals took off last year, one of the industry's biggest companies could make a splash in the sector in 2022.

By Ricky Zipp , Elise Reuter • Feb. 22, 2022

Diagnostics M&A expected to be strong in 2022 after dealmaking took off last year

Respondents to KPMG's survey predict that deal volumes and values for the diagnostics space will jump again this year as companies are ready to spend more of their COVID-19 cash.

By Nick Paul Taylor • Feb. 16, 2022

J&J's DePuy Synthes buys ortho company CrossRoads Extremity Systems

The deal, for an undisclosed amount, comes just weeks after Johnson & Johnson executives said the company will have a more aggressive M&A strategy going forward for the pharmaceutical and medical devices businesses.

By Ricky Zipp • Feb. 10, 2022

Healthcare staffing shortages a 'rising concern' for medtechs: Moody's

In a recent quarterly report, Moody's Investors Service called out hospital labor shortages as having a potential material impact on procedures in 2022, even as the omicron surge begins to decline.

By Elise Reuter • Feb. 9, 2022

4 key trends for procedure-reliant medtechs in 2022

Medical device companies likely will face the same challenges this year that they have been dealing with since the pandemic's start, such as procedure volatility and hospital staffing shortages.

By Ricky Zipp • Jan. 27, 2022

J&J's device recovery slowed by omicron surge, with impact expected over next several months

CFO Joseph Wolk said that the medtech giant expects pressure from COVID-19 and hospital staffing shortages to continue through the first half of 2022, with businesses recovering month by month.

By Ricky Zipp • Jan. 25, 2022

Medtech M&A, IPOs hit new highs as more buyers enter the space: SVB

In a new report, Silicon Valley Bank projects that medical device mergers and acquisitions "will stay hot, as a diverse set of acquirers compete for the top deals," but sees a slowdown in initial public offering activity.

By Nick Paul Taylor • Jan. 14, 2022

Medtronic CEO: Company on track to hit guidance, omicron impact 'uncertain'

Geoff Martha, who spoke on the opening day of J.P. Morgan's healthcare conference, said the medtech is being impacted by both the delta and omicron variants, including ongoing pressure from hospital staffing shortages.

By Ricky Zipp • Jan. 10, 2022